Oncotarget

Reviews:

Understanding the role of the kynurenine pathway in human breast cancer immunobiology

Benjamin Heng, Chai K. Lim, David B. Lovejoy, Alban Bessede, Laurence Gluch and Gilles J. Guillemin _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:6506-6520. https://doi.org/10.18632/oncotarget.6467

Metrics: PDF 2182 views  |   HTML 2397 views  |   ?  


Abstract

Benjamin Heng1, Chai K. Lim1, David B. Lovejoy1, Alban Bessede2, Laurence Gluch3 and Gilles J. Guillemin1

1 Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia

2 ImmuSmol, Pessac, France

3 The Strathfield Breast Centre, Strathfield, NSW, Australia

Correspondence to:

Gilles J. Guillemin, email:

Keywords: breast cancer, kynurenine pathway, immune-evasion

Received: July 13, 2015 Accepted: November 25, 2015 Published: December 04, 2015

Abstract

Breast cancer (BrCa) is the leading cause of cancer related death in women. While current diagnostic modalities provide opportunities for early medical intervention, significant proportions of breast tumours escape treatment and metastasize. Gaining increasing recognition as a factor in tumour metastasis is the local immuno-surveillance environment. Following identification of the role played by the enzyme indoleamine dioxygenase 1 (IDO1) in mediating maternal foetal tolerance, the kynurenine pathway (KP) of tryptophan metabolism has emerged as a key metabolic pathway contributing to immune escape. In inflammatory conditions activation of the KP leads to the production of several immune-modulating metabolites including kynurenine, kynurenic acid, 3-hydroxykynurenine, anthranilic acid, 3-hydroxyanthranilic acid, picolinic acid and quinolinic acid. KP over-activation was first described in BrCa patients in the early 1960s. More evidence has since emerged to suggest that the IDO1 is elevated in advanced BrCa patients and is associated with poor prognosis.  Further, IDO1 positive breast tumours have a positive correlation with the density of immune suppressive Foxp3+ T regulatory cells and lymph node metastasis. The analysis of clinical microarray data in invasive BrCa compared to normal tissue showed, using two microarray databank (cBioportal and TCGA), that 86.3% and 91.4% BrCa patients have altered KP enzyme expression respectively. Collectively, these data highlight the key roles played by KP activation in BrCa, particularly in basal BrCa subtypes where expression of most KP enzymes was altered. Accordingly, the use of KP enzyme inhibitors in addition to standard chemotherapy regimens may present a viable therapeutic approach.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6467